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Background: IL-25 is emerging as a key regulator of inflammation in the intestinal mucosa because of its ability to
promote type 2 while suppressing Th1 and Th17 responses. Several previous studies reported inconsistent results
on the role of exogenous IL-25 in development of colonic inflammation and none were performed in animals with
a genetic deletion of IL-25. We investigated the contribution of endogenous IL-25 to DSS-induced colitis using mice
deficient in IL-25.
Results: Mice were exposed to DSS in drinking water ad libitum either for seven days (acute) or for three cycles
of seven days with DSS followed by 14 days without DSS (chronic) to induce colitis, respectively. The loss of
body weight, appearance of diarrhea and bloody stools, and shortening of colon length were significantly less
pronounced in IL-25−/− mice compared to WT mice after exposure to acute DSS. Histological examination showed
that DSS-treated IL-25−/− mice had only mild inflammation in the colon, while severe inflammation developed in
DSS-treated WT mice. A significant up-regulation of IL-33 was observed in acute DSS-treated WT but not in the
IL-25−/− mice. There was significantly lower expression of pro-inflammatory cytokines in the colon of acute
DSS-treated IL-25−/− compared to WT mice. IL-25−/− mice were also partially protected from chronic DSS challenge
especially during the first 2 cycles of DSS exposure. In contrast to IL-25−/− mice, IL-13−/− mice were more susceptible
to DSS-induced colitis. Finally, stimulation of T84 colonic epithelial cells with IL-25 up-regulated the expression of IL-33
and several pro-inflammatory cytokines.
Conclusions: These data indicate that endogenous IL-25 acts as a pro-inflammatory factor in DSS-induced colitis,
which is unlikely to be mediated by IL-13 but possibly the induction of IL-33 and other pro-inflammatory mediators
from colonic epithelial cells. The present study suggests that IL-25 may contribute to the pathogenesis of inflammatory
bowel disease in at least a subgroup of patients.
Keywords: IL-25, Colitis, DSS, Mice, IL-13, IL-33Inflammatory bowel disease (IBD), a term that includes
both ulcerative colitis (UC) and Crohn’s disease (CD), is
characterized by chronic relapsing inflammation of the
intestine leading to diarrhea and abdominal pain. It is
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unless otherwise stated.IBD, with approximately 30,000 new cases diagnosed
each year [1]. There is no cure for IBD and the relapsing
course of the disease requires extended patient care with
progressive medical or surgical interventions to induce re-
mission [2]. Patients with long-standing colitis also have
an increased risk of developing colorectal cancer. Al-
though it is generally believed that IBD results from the
combination of alterations in the intestinal microbiome, a
genetic predisposition, and a dysregulated immune re-
sponse, the exact etiological factors and underlying mo-
lecular mechanisms for the pathogenesis of IBD remain totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wang et al. Cell & Bioscience 2014, 4:72 Page 2 of 10
http://www.cellandbioscience.com/content/4/1/72be fully elucidated [3-5]. Excessive cytokine responsive-
ness is a well recognized pathogenic factor important for
IBD. For example, patients with CD are often associated
with an exaggerated production of IFNγ, TNFα, and other
Th1-derived cytokines. Ulcerative colitis, on the other
hand, is considered to be an atypical Th2-mediated patho-
logy associated with increased production of IL-13 [6,7].
Nevertheless, increased expression of Th1 and Th17 cyto-
kines are reported in both CD and UC patients [8-12] and
anti-TNFα is therapeutically effective for both types of
IBD patients.
IL-25, also called IL-17E, is a member of IL-17 cytokine
family that includes IL-17A-F. While other members of
the IL-17 family have biological activities similar to Th1
inflammatory cytokines, IL-25 is involved in the pro-
motion of type 2 immunity including allergy, asthma, and
host immunity against parasitic nematode infection. In
addition, IL-25 is capable of inhibiting pro-inflammatory
Th1 and Th17 cytokine responses that are implicated in
various types of autoimmune diseases [13]. Mice with
IL-25 deficiency (IL-25−/−) develop severe intestinal in-
flammation during nematode infection implicating a
pivotal role of IL-25 in gut mucosal homeostasis [14,15].
In fact, both up-regulation and down-regulation of the
IL-25 expression in the colonic mucosa were reported in
patients with IBD or experimental murine models of col-
itis [16,17]. Several studies also showed that exogenous
IL-25 either ameliorates or aggravates colitis in mice de-
pending on the disease model of colitis employed ([6,18].
Notably, none of those studies were performed in mice
with a genetic deletion of IL-25, and therefore, a role for
endogenous IL-25 in the development of colonic inflam-
mation remains to be elusive.
Given that IL-25 has potent immune modulating activ-
ities especially in innate immunity and that dysregulated
innate immunity plays a dominant role in pathogenesis
of IBD, the current study investigated whether endoge-
nous IL-25 contributes to the development of colonic
inflammation using a model of dextran sulfate sodium
(DSS)-induced colitis in mice. Results from this study
showed reduced colitis in mice genetically lacking IL-25
after exposure to DSS, thus providing evidence that en-
dogenous IL-25 may have a pro-inflammatory role in the
development of colonic inflammation.
Results
Mice deficient in IL-25 are partially protected from
dextran sulfate sodium-induced acute and chronic colitis
To examine the role of endogenous IL-25 in the deve-
lopment of DSS-induced acute colitis, WT and IL-25−/−
mice received DSS in the drinking water ad libitum for
seven days and were euthanized on day eight. When
compared to WT mice, IL-25−/− mice lost significantly
less body weight (Figure 1A) and had less severe diseaseactivity based on combined clinical scores of stool con-
sistency, blood in the stool, and mouse appearance du-
ring the course of DSS exposure (Figure 1B). Both
strains of mice on DSS had shortened colon lengths as
compared to the vehicle-treated controls, however, the
shortening in IL-25−/− mice was significantly less than
that of DSS-treated WT mice (Figure 1C). Histological
evaluation of H&E-stained tissue sections of colon
showed that IL-25−/− mice treated with DSS had lower
HAI with only mild inflammation, while extensive in-
flammation developed in DSS-treated WT mice based
on the extent of focal crypt lesions, loss of goblet cells,
and infiltration of inflammatory cells (Figure 1D & E).
These results suggest that endogenous IL-25 plays a
pro-inflammatory role in DSS-induced acute colitis, ra-
ther than an anti-inflammatory role proposed by a pre-
vious study using exogenous IL-25 [19,20].
We next utilized a model of chronic DSS-induced coli-
tis to further evaluate the role of IL-25. As expected,
both WT and IL-25−/− mice lost body weight compared
to vehicle-treated controls, but gained body weight when
DSS treatment was interrupted. Notably, IL-25−/− mice
lost significantly less body weight during the first two
cycles of DSS exposure and recovered faster after the
switch back to water compared to DSS-treated WT mice
(Figure 2A). In addition, lower disease activity scores
were recorded in IL-25−/− mice than in WT mice when
examined at the end of first (day 7) and second (day 28)
cycle of DSS exposure (Figure 2B). However, as the third
cycle of DSS began, both IL-25−/− mice and WT mice
lost body weight in a similar more rapid rate than ob-
served in the first two cycles of DSS exposure. No diffe-
rences in weight loss between the DSS-treated IL-25−/−
and WT mice were detected during the third cycle of
DSS exposure, and the total clinical scores were similar
at day 49 (Figure 2B). At euthanasia, both IL-25−/− and
WT mice treated with DSS had a similar shortening of
colon length (Figure 2C), and microscopic examination
showed complete loss of crypts as well as extensive in-
flammatory cell infiltration in the muscularis mucosa,
submucosa, and muscularis externa (Figure 2D). Dra-
matic and similar smooth muscle hyperplasia/hypertro-
phy was also evident in both IL-25−/− and WT mice.
These results are consistent with the notion that mice
genetically deficient in IL-25 are only partially protected
from DSS-induced chronic colitis.
Associated changes in cytokine profile of the colon
To explore the potential mechanisms underlying the
relative protection of IL-25−/− mice against DSS-induced
colitis, we evaluated the immune response in colonic tis-
sues collected from mice exposed to acute or chronic
DSS treatment. qPCR analysis showed a significant up-
regulation of IL-33 in the colon of acute DSS-treated
Figure 1 Mice genetically deficient in IL-25 are protected from acute dextran sulfate sodium (DSS)-induced colitis. Mice were given 3.2%
DSS in drinking water for 7 days and euthanized at day 8. (A) Changes in body weight during the course of experiment, expressed as the percentage
of initial body weight at day 0; (B) Clinical disease activity based on stool consistency (0–3), presence of blood in stool (0–2), and general appearance
(0–2); (C) Colon length at euthanasia; (D) Representative H&E-stained colon sections (100X); (E) Histological activity index from a total score of epithelial
damage (0–4) and inflammatory cell infiltration (0–4). Data are mean ± SEM and are representatives of three independent experiments with five mice
per group. *P < 0.05 versus respective WT-DSS.
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reportedly contributes to intestinal inflammation [21,22].
However, the up-regulation of IL-33 was virtually absent
in acute DSS-treated IL-25−/− mice (Figure 3A). Signifi-
cantly increased levels of pro-inflammatory cytokines/
mediators TNFα, IL-6, IL-17A, IFNγ, and NOS2 were
also observed in the colons of both WT and IL-25−/−
mice post acute DSS treatment (Figure 3B). However,
the fold change in expression of these cytokines/media-
tors was significantly lower in IL-25−/− mice when com-
pared to WT mice (Figure 3B). The acute DSS-induced
up-regulation of expression for CD11b and CD11c,
markers of inflammatory cell infiltrates, was also less
pronounced in the colons of IL-25−/− than WT mice
(Figure 3C). However, we were unable to detect significant
differences in the colonic expression of pro-inflammatory
cytokine/mediators between WT and IL-25−/− mice whenthe samples were collected at the end of three cycles of
chronic DSS treatment (data not shown). This is con-
sistent with the observation that protection against DSS
colitis in IL-25−/− mice was lost by the third cycle of DSS
treatment.
Genetic deletion of IL-13 in mice increases susceptibility
to dextran sulfate sodium-induced colitis
IL-13 is one of the major downstream effector mole-
cules that mediates the biological activities of IL-25
[23]. To address whether resistance to DSS-induced col-
itis conferred by IL-25 deficiency was attributable to a
defect in IL-13 expression, we exposed IL-13−/− mice to
DSS for seven days. When compared with the age- and
sex-matched WT mice, IL-13−/− mice lost significantly
more body weight (Figure 4A) and developed exa-
cerbated disease activity (Figure 4B) during the course
Figure 2 Mice genetically deficient in IL-25 are partially protected from chronic dextran sulfate sodium (DSS)-induced colitis. Mice were
exposed to three cycles of DSS treatment. Each cycle of DSS involved seven days of DSS followed by 14 days on regular water. Mice were euthanized at
the eighth day of the third DSS cycle. (A) Body weight change expressed as the percentage of initial body weight at day 0; (B) Clinical disease activity
based on stool consistency (0–3), presence of blood in stool (0–2), and general appearance (0–2); (C) Colon length at euthanasia; (D) Representative
H&E-stained colon sections (100X) and the histological activity index from a total score of epithelial damage (0–4) and inflammatory cell infiltration
(0–4). Data are mean ± SEM and are representatives of two independent experiments with five or six mice per group. *P < 0.05 versus the
respective WT.
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IL-25−/− mice. At euthanasia, the extent of colon shor-
tening was worse in DSS-treated IL-13−/− mice than in
WT mice (Figure 4C). In addition, the colons from
DSS-treated IL-13−/− mice had significantly higher HAI
than that of DSS-treated WT mice, evidenced by the
presence of severe denudation of the surface epithelium,
extensive loss of crypts and separation of the crypt base
from the muscularis mucosa, as well as enhanced in-
flammatory cell infiltration in the submucosa (Figure 4D
& E). ELISA analysis of in situ cytokine production re-
vealed that the colons from DSS-treated IL-13−/− mice
produced significantly more IL-6, TNFα, and IL-17Athan that of DSS-treated WT mice (Figure 4F). Overall,
these results suggest that mice deficient in IL-13 have
increased susceptibility to acute DSS-induced colitis,
ruling out the possibility that the decreased suscep-
tibility to DSS-induced colitis in IL-25−/− mice is due to
a lack of IL-13.
Induction of pro-inflammatory cytokines/chemokines in
colonic epithelial cells by IL-25
Dysregulated function and immune response of the intes-
tinal epithelium are important contributors to intestinal
inflammation. A previous study showed that epithelial
cells produce and respond to IL-25 [24]. We cultured
Figure 3 Colonic expression of cytokines, mediators, and inflammatory cell markers. Mice genetically deficient in IL-25 and WT mice were
given 3.2% DSS in drinking water for 7 days and euthanized at day 8. qPCR was performed to examine mRNA expression of IL-33 (A), pro-inflammatory
cytokines/mediators (B), and inflammatory cell markers (C) in the colon. The fold changes are relative to the individual WT-VEH groups after normalization
to 18 s rRNA. Data are mean ± SEM and are representatives of two independent experiments with five mice per group. *P < 0.05 versus the respective
VEH; ϕ P < 0.05 versus respective WT-DSS.
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mine whether IL-25 directly stimulates epithelial cells to
produce pro-inflammatory cytokines that may contri-
bute to colitis. After stimulation with IL-25 for 24 hours,
T-84 cells expressed significantly higher levels of IL-33
(Figure 5). The results are consistent with in vivo results
showing that mice deficient in IL-25 produced less
IL-33 in the colon (Figure 3A). In addition, IL-25 in-
duced up-regulation of pro-inflammatory cytokines
TNFα and IL-6 as well as chemokines CCL2 and IL-8,
but did not affect the expression of IL-18 in T84 cells
(Figure 5).
Discussion
IL-25 is emerging as a key regulator of inflammation in
the intestinal mucosa because of its ability to promote
type 2 while suppressing Th1 and Th17 cytokineresponses. The role of IL-25 in the development of co-
lonic inflammation, however, remained to be fully eluci-
dated. As a primarily epithelial-derived cytokine in the
gastroenterological (GI) tract, IL-25 is an important
player in control of intestinal immunity and function.
Exogenous IL-25 induces strong type 2 immunity in the
GI tract characterized by increased expression of type 2-
related cytokines such as IL-5 and IL-13 [25,26], whereas
mice deficient in IL-25 have impaired ability to expel
parasitic worms and develop severe intestinal inflamma-
tion in response to enteric nematode infection [15,26].
IL-25 is also involved in the regulation of intestinal func-
tion including smooth muscle contraction, epithelial cell
secretion, as well as epithelial barrier function [26]. Re-
cent studies further identified type 2 innate lymphoid
cells as the key IL-25-responsive cells that produce IL-5
and IL-13, major downstream effector molecules of
Figure 4 Mice genetically deficient in IL-13 are more susceptible to acute dextran sulfate sodium (DSS)-induced colitis. Mice were given
3.0% DSS in drinking water for 7 days and euthanized at day 8. (A) Body weight change expressed as the percentage of initial body weight at
day 0; (B) Clinical disease activity based on stool consistency (0–3), presence of blood in stool (0–2), and general appearance (0–2); (C) Colon
length at euthanasia; (D) Representative H&E-stained colon sections (100X); (E) Histological activity index from a total score of epithelial damage
(0–4) and immune cell infiltration (0–4); (F) In situ cytokine production in the colon by ELISA. Data are mean ± SEM and are representatives of
two independent experiments with five mice per group. *P < 0.05 versus the respective VEH; ϕ P < 0.05 versus respective WT.
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however, inconsistent reports regarding the role of IL-25
in the development of colonic inflammation. Caruso
et al. reported that patients with either CD or UC had
significantly less IL-25 produced in the colon, implying
an anti-inflammatory role of IL-25 [16]. Of note, patients
with IBD are often accompanied by severe loss of intes-
tinal epithelium, which may account for the decrease in
IL-25 levels since it is expressed exclusively by epithelial
cells in the GI tract [16]. The same report also showed
that exogenous IL-25 ameliorated mouse TNBS colitis
that features up-regulation of pro-inflammatory Th1 cy-
tokines as seen in CD, or oxazolone colitis that has
histological characteristics and elevated production of
type 2 cytokines resembling UC patients [16]. On the
other hand, Camelo et al. showed that IL-25 mRNA was
modestly up-regulated in the colonic epithelial cells of
the mice during oxazolone colitis, and blocking IL-25
signaling via neutralizing IL-25 or IL-17RB considerably
improved the clinical aspects of the colitis [17]. Ourcurrent study demonstrated that mice genetically deficient
in IL-25 were partially protected from DSS-induced col-
itis, a model with a Th1/Th17 dominant response at the
early acute stage that shifts to a type 2 response in the
chronic stage [28]. This protection was observed in both
acute and chronic disease models, albeit with a loss in
protection over time after a third round of DSS treatment.
The relative resistance to colitis resulted from IL-25 defi-
ciency was evidenced by significantly decreased disease ac-
tivity as well as histological activity index, and was
associated with reduction of various pro-inflammatory cy-
tokines/mediators in the colon. Our results are contrary
to a previous study showing that exogenous IL-25 had an
inhibitory effect on the development of DSS colitis [19].
The reason for the inconsistency is not known, but a
follow-up study from the same group indicated that only
high doses (0.8 μg daily) of exogenous IL-25 protected,
while low doses (0.2 μg daily) of IL-25 aggravated the
DSS-induced colitis [20]. We made attempts to replicate
those studies with exogenous IL-25 [19,20], but the results
Figure 5 IL-25 induces up-regulation of cytokines in T84
colonic epithelial cells. T84 cells were cultured in a mixture of Ham’s
F12 and Dulbecco’s modified Eagle’s medium containing 5% FBS. One
million cells per well were seeded on a 6-well plate and incubated
overnight, and then treated with IL-25 (50 ng/ml) for 24 hours in
triplicates. Cells were collected for mRNA expression of cytokines by
qPCR. Data are mean ± SEM and are representatives of two independent
experiments. *P < 0.05 versus the respective vehicle.
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cantly reduced water/DSS consumption of the mice,
which altered the outcome (Zhao A, et al. unpublished re-
sults). It is possible that the decrease in DSS consumption
actually accounted for the protective effects of exogenous
IL-25 observed in the previous studies [19,20]. While none
of the previous studies were performed to understand the
role of endogenous IL-25 in mouse models of colitis, our
results demonstrate that constitutive IL-25 is a pro-
inflammatory factor for the development of DSS colitis in
mice and, therefore, may contribute to colonic inflamma-
tion in at least a subgroup of patients with IBD.
IL-33 is a recently identified member of the IL-1 cyto-
kine family and is expressed by many types of cell ranging
from major innate immune cells to non-hematopoietic
structural cells throughout the GI tract [29,30]. Similarly
to IL-25, epithelial-derived IL-33 is thought to be import-
ant in initiating type 2 immunity especially in the intestine
and lung [31]. A role of IL-33 for colonic inflammation
has been suggested based on several recent studies [32].
Expression of IL-33 and its ST2 receptor was consistently
up-regulated in the intestinal mucosa of patients with UC
and to a lesser extent in CD patients, as well as animals
with colitis [22,33]. In addition, ST2 deficiency led to
decreased disease severity in TNBS- and DSS-induced
mouse models of colitis whereas exogenous IL-33 exacer-
bated DSS-colitis [22]. We and others showed that both
IL-25 and IL-33 can impair intestinal epithelial barrierfunction that may potentiate inflammation [22,26,34]. In
the current study, we replicated previous results [21,22]
that showed up-regulation of IL-33 in DSS-induced colitis
and, more importantly, demonstrated that resistance of
IL-25−/− mice to DSS-induced colitis was associated with
diminished IL-33 expression in the colon. These results
suggest that IL-25 may activate IL-33 signaling leading to
heightened inflammation. Indeed, both epithelial cells and
lamina propria immune cells in the GI tract express the
IL-17RB and IL-17RA receptor subunits for IL-25 that are
regulated by immune mediators including IL-25 [26], and
exogenous administration of IL-25 to mice increases the
expression of IL-33 in the intestine [24]. We showed pre-
viously that exogenous IL-33 also up-regulated the expres-
sion of IL-25 [34]. These results suggest that there is a
positive feedback loop between IL-25 and IL-33 that po-
tentiates the biological activities. Our current results ex-
tend this observation by showing that IL-25 can directly
act on a cell line of colonic epithelial cells to induce IL-33
expression.
Among the identified downstream effector molecules of
IL-25, IL-13 is critical for the promotion of type 2 immu-
nity important for clearance of parasitic nematode infec-
tions and for the characteristic changes in gut function
after nematode infection (35). Indeed, exogenous IL-25
could not restore the host protective immunity or hyper-
contractility in IL-13−/− mice after Nippostrongylus brasi-
liensis infection [35]. IL-13 appears to also play a role in
the pathogenesis of IBD especially UC, since levels of
IL-13 were increased in patients with UC [36] and block-
age of IL-13 was effective in treatment of murine colitis
induced by oxazolone [37]. The observed resistance to
DSS-induced colitis in IL-25−/− mice led us to investigate
whether this was related to defective IL-13 expression. In
the present study, however, mice with a genetic IL-13 defi-
ciency had significantly more severe colitis after exposure
to DSS contrary to that observed in IL-25−/− mice, indicat-
ing an anti-inflammatory effect of IL-13. Since IL-13 acts
almost exclusively through intracellular STAT6 signaling
pathway for its biological activities [38], our results are
consistent with a previous study showing that DSS-
induced colitis was exacerbated in mice deficient in
STAT6 because the defective IL-13 signaling led to a
higher level of IFNγ [39]. On the other hand, our results
from IL-13−/− mice on a C57BL/6 background are con-
trary to a recent study using IL-13−/− mice on a BALB/c
background that showed reduced severity of DSS-induced
colitis accompanied by decreased number of enterochro-
maffin cell and colonic serotonin content [40]. It is known
that mice on a C57BL/6 background are prone to Th1 im-
munity, whereas mice on BALB/c background are biased
toward type 2 immunity. Whether the differences in
genetic background contribute to the disparate results re-
mains to be determined.
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epithelial barrier function and mucosal immunity in the
development of IBD [41]. Intestinal epithelial cells that
line the surface of the gut serve as the initial barrier to
prevent antigens from penetrating the intestinal mucosa.
Defects in the intestinal epithelial barrier allow the
direct exposure of mucosa immune cells to harmful
luminal contents, resulting in the production of pro-
inflammatory cytokines that are implicated in the pa-
thogenesis of IBD. In addition, intestinal epithelial cells
produce cytokines and chemokines that regulate the re-
cruitment of inflammatory cells. Therefore, intestinal epi-
thelial cells orchestrate the mucosal immune homeostasis
and are one of the major players in the development of in-
testinal inflammation [41]. Among the cytokines/che-
mokines produced by epithelial cell, TNFα and IL-6 are
considered to be central to the pathogenesis of IBD while
CCL2 and IL-8 are the major players for the recruitment
of inflammatory cells. Our current study showed that
direct stimulation of a cell line of colonic epithelial cells
with IL-25 increased expression of IL-6, TNFα, as well as
IL-8 and CCL2, providing a potential mechanism by
which IL-25 contributes to DSS-induced colitis. Together
with their ability to produce IL-33 in response to IL-25,
intestinal epithelial cells are likely an important player
mediating the pro-inflammatory role of IL-25 in DSS-
induced colitis.
Conclusions
Type 2 immunity is essential for host protection against
parasitic nematode infection while is detrimental in cer-
tain type 2-mediated inflammatory pathologies. Our
present study shows that mice deficient in IL-25 are
partially protected from DSS-induced colitis in mice
associated with lower expression of IL-33 and other pro-
inflammatory cytokines/mediators in the colon. In con-
trast, mice deficient in IL-13 are more susceptible to the
colitis indicating the protection conferred by IL-25 defi-
ciency is unlikely due to a lack of IL-13. Since IBD is a
heterogeneous group of chronic inflammatory disorders
of the GI tract in that various immune factors are impli-
cated, the current study provides genetic evidence for
the first time that constitutively expressed IL-25 may




C57BL/6 wild type (WT) mice were purchased from
National Cancer Institute Mouse Repository (Frederick,
MD 21702). Mice deficient in IL-25 (IL-25−/−) were ge-
nerated in a mixed background by Regeneron Pharma-
ceuticals (Tarrytown, NY) [26]. Mice deficient in IL-13
(IL-13−/−) were generated in a mixed background [42] andmanaged by Taconic at the National Institutes of Allergy
and Infectious Diseases. These mice were backcrossed to
C57BL/6 mice for at least 10 generations after being re-
ceived, which is considered fully congenic and therefore
C57BL/6 WT mice were used as the controls. To avoid
the potential confounding effects from differences in the
colonic microbiome, all mice with expanded numbers
were bred in the USDA/Beltsville animal facility so that
they were expected to have the same level of environmen-
tal exposure to microbes. All mice were used at the age of
10 to 14 week old and all studies were conducted with in-
stitutional approval from both the University of Maryland,
Baltimore and the USDA Beltsville Area Animal Care and
Use Committees (protocol #13-003) in accordance with
principles set forth in the Guide for Care and Use of
Laboratory Animals, Institute of Laboratory Animal Re-
sources, National Research Council, Health and Human
Services Publication (National Institutes of Health 85–23,
revised 1996).
Induction of DSS colitis in mice
To induce acute colitis, mice (n = 5/group) were admin-
istrated 3.0 or 3.2% DSS (mol. wt. 35,000 to 50,000 Da;
MP Biochemicals, Santa Ana, CA) in their drinking
water ad libitum for seven days and euthanized on day
eight. For induction of chronic colitis, mice were ex-
posed to three cycles of 3.2% DSS treatment for seven
days each followed by a 14 day interval on regular water
[43]. Mice were euthanized one day after the last DSS
treatment. Mice on regular drinking water were used as
vehicle controls. Age- and sex-matched WT and genetic-
ally deficient mice were used throughout the studies.
The baseline body weight was not significantly different
among the groups of WT, IL-25−/−, and IL-13−/− mice
when the treatments started.
Clinical scoring and histological assessment of colitis
During the course of experiments, mice were scored for
stool consistency (0–3), presence of blood in stool (0–2),
and general appearance (0–2) according to the published
“Clinical Scoring Criteria” [43]. These scores were added
to generate a total clinical score ranging from 0 to 7.
When mice were euthanized, the entire colon was
quickly removed and the length of the colon was mea-
sured. Segments of distal colon were fixed in 4% parafor-
maldehyde for 4 hours. Tissue sections (4 μm) of distal
colon were cut from paraffin-embedded blocks and
stained with hematoxylin and eosin (H&E). Histological
assessment of colitis was performed by an investigator
who was unaware of the mouse genotype and treatment
using established criteria with slight modification [28,44].
Histological activity index (HAI) was a total score of
epithelial damage (0–4) and inflammatory cell infiltration
(0–4) ranging from 0 to 8 [28,44].
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T84 cells (CCL-248, ATCC), a human colonic epithelial
cell line, were cultured in a mixture of Ham’s F12 and
Dulbecco’s modified Eagle’s medium containing 5% FBS.
1 × 106 cells per well were seeded in a 6-well plate and
incubated at 37°C with 5% CO2 overnight. The cell
monolayer was then treated with recombinant IL-25
(50 ng/ml) from Biolegend (San Diego, CA 92121) for
24 hours. After treatment, cell monolayers were col-
lected with Trizol for subsequent RNA isolation and
cytokine expression analysis by qPCR.
RNA extraction, cDNA synthesis, real-time quantitative
PCR (qPCR), and ELISA
Total RNA was extracted from cells and tissues with TRIzol
reagent (Invitrogen, Grand Island, NY) as per the manu-
facturer’s instructions. One-centimeter of distal colon was
collected and the whole tissue was processed for RNA iso-
lation. RNA samples (2 μg) were reverse-transcribed to
cDNA using the First Strand cDNA Synthase Kit (MBI
Fermentas, Hanover, MD) with random hexamer primer.
qPCR was performed on a CFX96 Touch Real-Time De-
tection System (Bio-Rad, CA) in a 25 μl volume using
SYBR green Supermix (Bio-Rad, Hercules, CA). Amplifi-
cation conditions were: 95°C for 3 min, 50 cycles of 95°C
for 15 s, 60°C for 15 s, and 72°C for 20s. The fold-changes
in mRNA expression for targeted genes were relative
to the respective groups of vehicle-treated mice after
normalization to 18 s rRNA. Tissue homogenates of co-
lonic whole tissues were prepared with RIPA buffer (Cell
signaling technology, Beverly, MA) and in situ cytokine
production of TNFα, IL-6, and IL-17A in the homo-
genates was measured using LEGEND MAX™ Mouse
ELISA Kit (BioLegend, San Diego, CA) following manu-
facturer's instructions.
Data analysis
Statistical analysis was performed using one-way ANOVA
followed by Neuman-Keuls test to compare the difference
among three or more treatment groups or the Student
t test to compare the difference between two groups.
P values of <0.05 were considered significant.
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